Distributor inventory | Tablet
Voglibose 0.2 mg + Repaglinide 0.5 mg tablet
Type 2 diabetes mellitus: to improve post-meal and overall blood glucose control when diet and exercise alone are insufficient; used when combination therapy is required.
Voglibose is an alpha-glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine, reducing post-meal glucose spikes. Repaglinide is a short-acting insulin secretagogue (meglitinide) that stimulates pancreatic insulin release, mainly around meals, thereby lowering postprandial blood glucose.
Oral tablet. Take exactly as prescribed. Typically taken before meals (repaglinide is usually taken 15–30 minutes before each main meal; skip the dose if you skip a meal). Voglibose is usually taken just before/with the first bite of meal. Follow your doctor’s instructions for this fixed-dose combination; monitor blood glucose regularly.
Common side effects of VOLIBO R 0.2/0.5MG TAB may include:
Risk of hypoglycaemia (higher with missed meals, excessive exercise, alcohol, or with other antidiabetics); do not take repaglinide component if a meal is skipped. Use caution in hepatic impairment; monitor liver function if advised. Use with caution in renal impairment and in elderly. Voglibose may cause GI symptoms (gas/diarrhoea). Not for type 1 diabetes or diabetic ketoacidosis. Inform doctor about frequent hypoglycaemia, irregular meals, or planned surgery/acute illness.
